[Current standards in the treatment of gastric cancer].
Endoscopic resection is established in the treatment of early gastric cancer. More advanced gastric cancer requires gastrectomy and D2 lymphadenectomy. Perioperative chemotherapy improves overall survival in locally advanced gastric cancer representing a standard of care. Locally advanced adenocarcinomas of the esophago-gastric junction can alternatively be treated with concurrent radiochemotherapy. In metastatic disease, systemic chemotherapy improves survival, quality of life and symptom control. Trastuzumab plus chemotherapy should be used together with first-line chemotherapy in HER2 positive gastric cancer patients. Second- and third-line therapy is now well established. The anti-VEGFR2 antibody Ramucirumab improves survival in second line treatment both as a monotherapy and in combination with paclitaxel and represents a novel treatment option.
Universitäres Krebszentrum Leipzig, Universitätsklinikum Leipzig.
Ulrich
U
Hacker
Universitäres Krebszentrum Leipzig, Universitätsklinikum Leipzig.
Florian
F
Lordick
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant; D003131:Combined Modality Therapy; D018450:Disease Progression; D005773:Gastroscopy / Q000379:methods*; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D009367:Neoplasm Staging; D010166:Palliative Care; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate